Scholar Rock/SRRK

$12.49

-12.77%
-
1D1W1MYTD1YMAX

About Scholar Rock

Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of medicines for the treatment of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. The Company’s product candidate includes apitegromab, an inhibitor of the activation of latent myostatin for the treatment of spinal muscular atrophy (SMA) and is in the treatment of other myostatin-related disorders. Its product candidate also includes SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 (TGFb1) for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies. The Company is advancing multiple antibody profiles toward product candidate selection, including antibodies that selectively inhibit the activation of latent TGFb1 in the context of fibrotic extracellular matrix and that avoid perturbing TGFb1 presented by cells of the immune system.

Ticker

SRRK

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jay Backstrom

Employees

150

Headquarters

Cambridge, United States

Scholar Rock Metrics

BasicAdvanced
$1.1B
Market cap
-
P/E ratio
-$2.09
EPS
0.87
Beta
-
Dividend rate
$1.1B
0.86629
$21.17
$5.56
845K
6.584
24.399
27.408
-62.98%
-89.09%
-70.72%
6.126
6.126
19.43%

What the Analysts think about Scholar Rock

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 8 analysts.
110.17% upside
High $30.00
Low $20.00
$12.49
Current price
$26.25
Average price target

Scholar Rock Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$57M
23.21%
Profit margin
0%
NaN%

Scholar Rock Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 15.86%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.47
-$0.53
-$0.50
-$0.59
-
Expected
-$0.56
-$0.52
-$0.49
-$0.51
-$0.61
Surprise
-15.36%
1.75%
2.56%
15.86%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Scholar Rock stock?

Scholar Rock (SRRK) has a market cap of $1.1B as of May 18, 2024.

What is the P/E ratio for Scholar Rock stock?

The price to earnings (P/E) ratio for Scholar Rock (SRRK) stock is 0 as of May 18, 2024.

Does Scholar Rock stock pay dividends?

No, Scholar Rock (SRRK) stock does not pay dividends to its shareholders as of May 18, 2024.

When is the next Scholar Rock dividend payment date?

Scholar Rock (SRRK) stock does not pay dividends to its shareholders.

What is the beta indicator for Scholar Rock?

Scholar Rock (SRRK) has a beta rating of 0.87. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Scholar Rock stock price target?

The target price for Scholar Rock (SRRK) stock is $26.25, which is 110.17% above the current price of $12.49. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Scholar Rock stock

Buy or sell Scholar Rock stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing